WallStreetZenWallStreetZen

NASDAQ: MNKD
Mannkind Corp Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for MNKD

Based on 1 analyst offering 12 month price targets for Mannkind Corp.
Min Forecast
$6.00+100%
Avg Forecast
$6.00+100%
Max Forecast
$6.00+100%

Should I buy or sell MNKD stock?

Based on 1 analyst offering ratings for Mannkind Corp.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their MNKD stock forecasts and price targets.

MNKD stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
HC Wainwright & Co.
Bottom 4%
4
BuyMaintains$6.00+100.00%2022-02-28

1 of 1

Forecast return on equity

Is MNKD forecast to generate an efficient return?
Company
-34.37%
Industry
18.62%
Market
118.31%
MNKD's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MNKD forecast to generate an efficient return on assets?
Company
29.71%
Industry
14.14%
MNKD is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MNKD earnings per share forecast

What is MNKD's earnings per share in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
-$0.38
Avg 2 year Forecast
-$0.13
Avg 3 year Forecast
$0.16

MNKD revenue forecast

What is MNKD's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$85.1M+29.75%
Avg 2 year Forecast
$170.2M+159.41%
Avg 3 year Forecast
$249.4M+280.1%
MNKD's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

MNKD revenue growth forecast

How is MNKD forecast to perform vs Biotechnology companies and vs the US market?
Company
56.34%
Industry
23.9%
Market
8.47%
MNKD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
MNKD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

MNKD vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MNKD$3.00$6.00+100.00%Buy
KNSA$11.06$34.00+207.41%Strong Buy
ACLX$17.76$31.33+76.42%Strong Buy
PNT$8.35$28.17+237.33%Strong Buy
TBPH$9.84$11.50+16.87%Hold

Mannkind Stock Forecast FAQ

Is Mannkind Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: MNKD) stock is to Buy MNKD stock.

Out of 1 analyst, 0 (0%) are recommending MNKD as a Strong Buy, 1 (100%) are recommending MNKD as a Buy, 0 (0%) are recommending MNKD as a Hold, 0 (0%) are recommending MNKD as a Sell, and 0 (0%) are recommending MNKD as a Strong Sell.

If you're new to stock investing, here's how to buy Mannkind stock.

What is MNKD's earnings growth forecast for 2022-2024?

(NASDAQ: MNKD) Mannkind's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 8.59%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.45%.

Mannkind's earnings in 2022 is -$87,508,000.On average, 4 Wall Street analysts forecast MNKD's earnings for 2022 to be -$97,788,538, with the lowest MNKD earnings forecast at -$118,375,599, and the highest MNKD earnings forecast at -$77,201,478. On average, 4 Wall Street analysts forecast MNKD's earnings for 2023 to be -$33,453,974, with the lowest MNKD earnings forecast at -$51,467,652, and the highest MNKD earnings forecast at $5,146,765.

In 2024, MNKD is forecast to generate $41,174,121 in earnings, with the lowest earnings forecast at $20,587,061 and the highest earnings forecast at $61,761,182.

What is MNKD's revenue growth forecast for 2022-2024?

(NASDAQ: MNKD) Mannkind's forecast annual revenue growth rate of 56.34% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 23.9%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 8.47%.

Mannkind's revenue in 2022 is $65,612,000.On average, 3 Wall Street analysts forecast MNKD's revenue for 2022 to be $21,907,978,003, with the lowest MNKD revenue forecast at $20,844,398,979, and the highest MNKD revenue forecast at $23,314,846,265. On average, 3 Wall Street analysts forecast MNKD's revenue for 2023 to be $43,799,229,020, with the lowest MNKD revenue forecast at $40,299,171,359, and the highest MNKD revenue forecast at $49,564,635,375.

In 2024, MNKD is forecast to generate $64,177,073,735 in revenue, with the lowest revenue forecast at $57,849,640,623 and the highest revenue forecast at $70,504,506,848.

What is MNKD's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: MNKD) forecast ROA is 29.71%, which is higher than the forecast US Biotechnology industry average of 14.14%.

What is MNKD's Price Target?

According to 1 Wall Street analyst that have issued a 1 year MNKD price target, the average MNKD price target is $6.00, with the highest MNKD stock price forecast at $6.00 and the lowest MNKD stock price forecast at $6.00.

The Wall Street analyst predicted that Mannkind's share price could reach $6.00 by Feb 28, 2023. The average Mannkind stock price prediction forecasts a potential upside of 100% from the current MNKD share price of $3.00.

What is MNKD's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: MNKD) Mannkind's current Earnings Per Share (EPS) is -$0.34. On average, analysts forecast that MNKD's EPS will be -$0.38 for 2022, with the lowest EPS forecast at -$0.46, and the highest EPS forecast at -$0.30. On average, analysts forecast that MNKD's EPS will be -$0.13 for 2023, with the lowest EPS forecast at -$0.20, and the highest EPS forecast at $0.02. In 2024, MNKD's EPS is forecast to hit $0.16 (min: $0.08, max: $0.24).

What is MNKD's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: MNKD) forecast ROE is -34.37%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.